Exchange: NASDAQ·Updated 07:59 PM EDT

TENX News

News
all
press releases
Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky
Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky Tenax Therapeutics (TENX) Securities Investigation Notice - Levi & Korsinsky PR Newswire NEW YORK, Aug. 19, 2026 Tenax Therapeutics shares fell approximately 84% to 85% after the Company disclosed that its Phase 3 LEVEL...
PR Newswire
More News
TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tenax Therapeutics, Inc. (Tenax or the Company) (NASDAQ: TENX) for violations of the securities laws. INVESTIGATION DETAILS: The investigation...
Business Wire
TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)
A single clinical readout drove Tenax Therapeutics (NASDAQ: TENX) shares down approximately 84% to 85% shareholder after the Company disclosed that its Phase 3 LEVEL trial of TNX-103 in PH-HFpEF missed both its primary and key secondary endpoints. If you held TENX shares and suffered a loss, you...
Business Wire
TENX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Tenax Therapeutics
TENX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Tenax Therapeutics TENX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Tenax Therapeutics PR Newswire NEW YORK, Aug. 13, 2026 Tenax Therapeutics...
PR Newswire
Tenax Therapeutics Stock Dives as It Faces Heart Drug Study Setback
Tenax Therapeutics announced Phase 3 LEVEL trial results for TNX-103, missing primary endpoints while showing subgroup benefits.read more...
Benzinga
Why Did TENX Stock Crash 89% Today?
The biotech firm’s experimental drug TNX-103 failed to meet the main goal of a late-stage study in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction.
Stocktwits
Futures Erase Overnight Gains As Oil Hits One-Week High, Yen Slides
Futures Erase Overnight Gains As Oil Hits One-Week High, Yen Slides US equity futures start the new week barely higher, having erased almost all of their overnight gains, yet still trading at all time highs, led by Tech with small caps starting the week in the red. As of 8:00am ET, S&P...
Zero Hedge
Wall Street Analysts Predict a 121.36% Upside in Tenax Therapeutics (TENX): Here's What You Should Know
The mean of analysts' price targets for Tenax Therapeutics (TENX) points to a 121.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Rivian Automotive, Tenax Therapeutics, Robinhood And Other Big Stocks Moving Higher On Thursday
Rivian Automotive Inc (RIVN) gained 12.2% after strong Q2 production figures and raised delivery forecast. Other companies such as Nexa Resources SA (NEXA) and Moderna Inc (MRNA) also saw gains in today's session.read more...
Benzinga
Tenax Therapeutics, Inc. (NASDAQ:TENX) Given Consensus Rating of "Moderate Buy" by Brokerages
Shares of Tenax Therapeutics, Inc. (NASDAQ:TENX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the six research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have assigned a buy...
MarketBeat

Advertisement|Remove ads.